A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.

HFCAS OpenIR

	A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
	Yu, Pengfei ; Du, Yian ; Xu, Zhiyuan ; Yang, Litao ; Ying, Jieer ; Wang, Yongxiang ; Chen, Ping ; Wei, Yunhai ; Xu, Hongtao ; Xu, Nong ; Cheng, Xiangdong
	2022-06-01
发表期刊	JOURNAL OF CLINICAL ONCOLOGY
ISSN	0732-183X
收录类别	SCI
语种	英语
资助项目	CSPC Pharmaceutical Group Co., Ltd.
项目资助者	CSPC Pharmaceutical Group Co., Ltd.
WOS研究方向	Oncology
WOS类目	Oncology
WOS记录号	WOS:000863680301218
出版者	LIPPINCOTT WILLIAMS & WILKINS
引用统计
文献类型	期刊论文
条目标识符	http://ir.hfcas.ac.cn:8080/handle/334002/129940
专题	中国科学院合肥物质科学研究院
作者单位	1.Univ Chinese Acad Sci, Canc Hosp, Zhejiang Canc Hosp, Hangzhou, Peoples R China 2.Ningbo Second Hosp, Ningbo, Peoples R China 3.Zhejiang Univ, Huzhou Hosp, Huzhou Cent Hosp, Huzhou, Peoples R China 4.Lishui Cent Hosp, Lishui, Peoples R China 5.Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Yu, Pengfei,Du, Yian,Xu, Zhiyuan,et al. A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.[J]. JOURNAL OF CLINICAL ONCOLOGY,2022,40.
APA	Yu, Pengfei.,Du, Yian.,Xu, Zhiyuan.,Yang, Litao.,Ying, Jieer.,...&Cheng, Xiangdong.(2022).A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection..JOURNAL OF CLINICAL ONCOLOGY,40.
MLA	Yu, Pengfei,et al."A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.".JOURNAL OF CLINICAL ONCOLOGY 40(2022).